RADIATION THERAPY FOR HIGH-RISK ASYMPTOMATIC BONE METASTASES: A PRAGMATIC MULTICENTER RANDOMIZED PHASE 3 CLINICAL TRIAL (PREEMPT)

A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF LYL314, A CD19/CD20 DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PARTICIPANTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF LYL314, A CD19/CD20 DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PARTICIPANTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation”

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation”

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

A RANDOMIZED PHASE III TRIAL INCORPORATING PATHOLOGIC COMPLETE RESPONSE IN PARTICIPANTS WITH EARLY STAGE NON SMALL CELL LUNG CANCER TO OPTIMIZE IMMUNOTHERAPY IN THE ADJUVANT SETTING (INSIGHT)

A RANDOMIZED PHASE III TRIAL INCORPORATING PATHOLOGIC COMPLETE RESPONSE IN PARTICIPANTS WITH EARLY STAGE NON SMALL CELL LUNG CANCER TO OPTIMIZE IMMUNOTHERAPY IN THE ADJUVANT SETTING (INSIGHT)

A Randomized Phase III Trial of Checkpoint blockade in Lung cancEr patients in the Adjuvant setting based on pathologic Response following neoadjuvant therapy (CLEAR)